UC Irvine

UC Irvine Previously Published Works

Title

Lung function 5 yr after lung volume reduction surgery for emphysema.

Permalink

<https://escholarship.org/uc/item/8gc618dj>

Journal

American journal of respiratory and critical care medicine, 163(7)

ISSN

1073-449X

Authors

Gelb, AF
McKenna, RJ
Brenner, M
et al.

Publication Date

2001-06-01

DOI

10.1164/ajrccm.163.7.2009048

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Lung Function 5 yr after Lung Volume Reduction Surgery for Emphysema

ARTHUR F. GELB, ROBERT J. McKENNA, JR., MATTHEW BRENNER, JOEL D. EPSTEIN, and NOE ZAMEL

Pulmonary Division, Department of Medicine, Lakewood Regional Medical Center, University of California, Los Angeles, California; School of Medicine, University of California, Irvine, California; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Thoracic Surgery, Chapman Medical Center, Orange, California; and Cedars-Sinai Medical Center and University of California, Los Angeles, California

Current datum more than 2 yr after lung volume reduction surgery (LVRS) for emphysema is limited. This prospective study evaluates pre-LVRS baseline and 5-yr results in 26 symptomatic patients (mean age 67 ± 6 yr) (mean $\pm$ SD) who underwent bilateral, targeted upper lobe stapled LVRS using video-assisted thoracoscopy. Baseline forced expiratory volume in 1 s (FEV_1) was 0.7 ± 0.2 L (mean $\pm$ SD), $29 \pm 10\%$ predicted. Following LVRS, with none lost to follow-up, mortality due to respiratory failure at 0.5, 1, 2, 3, 4, and 5 yr was 4%, 4%, 19%, 31%, 46%, and 58%, respectively. Increase above baseline for $FEV_1 > 200$ ml and/or FVC > 400 ml at 1, 2, 3, 4, and 5 yr post-LVRS was noted in 73%, 46%, 35%, 27%, and 8% of all patients; decrease in dyspnea grade ≥ 1 in 88%, 69%, 46%, 27%, and 15%; and elimination of initial oxygen dependence in 18 patients in 78%, 50%, 33%, 22%, and 0%, respectively. Expiratory airflow improved due to the increase in both lung elastic recoil and small airway intraluminal caliber. Five patients decreased FEV_1 141 ± 60 ml/yr and FVC 102 ± 189 ml/yr over 3.8 ± 1.2 yr post-LVRS, similar to their pre-LVRS rate of decline. In the 11 patients who survived 5 yr, at 0.5–1.0 yr post-LVRS peak increase in FEV_1 was 438 ± 366 ml, with a decline of 149 ± 157 ml the following year and 78 ± 59 ml/yr over 4.0–4.5 yr. Bilateral LVRS provided palliative clinical and physiological improvement in 9 of 26 patients at 3 yr, 7 at 4 yr, and 2 at 5 yr.

Despite best medical therapy, patients with severe chronic airflow limitation due to emphysema suffer from progressive dyspnea, poor exercise tolerance with increased morbidity, and mortality compared to age-matched normal cohorts. When the forced expiratory volume in 1 s (FEV_1) is < 0.75 L or 30% predicted, mortality of 40% to 50% at 3 yr has been noted (1, 2). Furthermore, patients older than 65 yr of age hospitalized in the intensive care unit for an exacerbation of chronic obstructive lung disease, irrespective of the need for invasive or noninvasive ventilation, have an overall 1-yr mortality rate of 30%; whereas in other similar patients older than 65 yr of age, mortality rate is 60% (3).

The surgical modification of lung volume reduction surgery (LVRS) by Meyers and coworkers (4) resulted in marked improvement in dyspnea, exercise tolerance, and lung function. The 2-yr post-LVRS results are in contrast to the progressive deterioration in similar patients accepted for, but denied LVRS by Medicare, and followed for a similar time (4). Prospective long-term studies, beyond 2 yr after LVRS, are very limited (4–6).

We report our prospective 5-yr results following LVRS in 26 patients with non- α_1 -antitrypsin deficiency emphysema with none lost to follow-up.

METHODS

Patient Selection

As previously reported (6, 7), the patients with emphysema were markedly symptomatic with grade ≥ 3 dyspnea (able to walk ≤ 100 yd), and had exhausted best medical therapy. This included antibiotics, aerosol and oral bronchodilators, including short-acting and long-acting β_2 -agonists, ipratropium bromide, corticosteroids, and repeated attempts at physical conditioning. High-resolution, thin-section computerized tomography (CT) lung demonstrated emphysema severity scores ≥ 60 with heterogeneous distribution, that is, more severe emphysematous destruction predominantly in the upper half lung field, score 84 ± 12 (mean $\pm$ SD), compared with 62 ± 15 in the lower half lung field. These ranking scores from 0 to 100 (worst) are a modification of the anatomic emphysema picture-grading technique (6, 7). Nuclear medicine perfusion scans demonstrated similar heterogeneous distribution. Smoking history was 52 ± 13 pack-years (mean $\pm$ SD). Patients ceased cigarettes smoking ≥ 6 mo prior to LVRS. Significant peak systolic pulmonary artery hypertension ≥ 45 mm Hg was excluded by clinical and echocardiogram evaluation.

Operative Technique

As previously reported (6), from January to June 1995, after obtaining informed consent, 82 patients underwent immediate sequential, bilateral stapled lung volume reduction for emphysema, using video-assisted thoracoscopic surgery (VATS). Surgical technique and selection have been previously reported (6, 7). It was estimated that approximately 20% to 30% of each lung was excised, and resected lung weighed 30–90 g. Twenty-six of the 82 patients agreed to undergo additional studies, including lung elastic recoil, both pre- and postoperatively, and form the basis of this prospective study.

Lung Function Studies

As previously noted (6, 7), we obtained informed consent and measured lung function and exercise studies after three inhalations (670 μ g) of aerosolized albuterol.

Follow-up

All patients were followed for up to 5 yr post-LVRS unless death intervened. No patient was lost to follow-up.

RESULTS

The results of preoperative lung function studies in the 26 patients (18 men), aged 67 ± 6 yr (mean $\pm$ SD) are reported in Table 1. Preoperative spirometry, lung volumes, and diffusing capacity in the 26 patients were not significantly ($p > 0.05$) different from the other 56 patients (data not shown) who underwent LVRS during the same study period, but were not studied in greater physiological detail. Baseline results for 21 of the 26 patients (data not shown) were not significantly different from five patients who had serial annual spirometry prior to LVRS. Although overall smoking history was similar, the

(Received in original form September 17, 2000 and in revised form February 22, 2001)

Supported by DOE (Department of Energy) Grant DE-FG03-91ER61227, American Lung Association Grant CI-030-N, and CTRDRP (California Tobacco Related Disease Research Program) 9RT-0094.

Correspondence and requests for reprints should be addressed to Arthur F. Gelb, M.D., 3650 E. South St., Suite 308, Lakewood, CA 90712. E-mail: afgelb@msn.com

Am J Respir Crit Care Med Vol 163, pp 1562–1566, 2001

Internet address: www.atsjournals.org

TABLE 1. BASELINE DATA (MEAN $\pm$ SD) ON ALL 26 LVRS PATIENTS AND 5 LVRS PATIENTS WITH SERIAL ANNUAL SPIROMETRY DATA PRIOR TO LVRS*

	LVRS (n = 26, 18 men)	% Pred or Normal	LVRS Patients Who Had Serial Spirometry Prior to LVRS (n = 5, 3 men)	% Pred
Age	67 $\pm$ 6 yr		69 $\pm$ 5	
VC	2.4 $\pm$ 0.7 L	67 $\pm$ 6	2.8 $\pm$ 0.8	70 $\pm$ 14
FVC	2.1 $\pm$ 0.6 L	58 $\pm$ 14	2.3 $\pm$ 0.6	57 $\pm$ 11
FEV ₁	0.7 $\pm$ 0.2 L	29 $\pm$ 10	0.7 $\pm$ 0.2	26 $\pm$ 6
TLC	8.6 $\pm$ 1.8 L	147 $\pm$ 17	8.9 $\pm$ 1.9	150 $\pm$ 16
RV	6.0 $\pm$ 1.4 L	268 $\pm$ 46	6.2 $\pm$ 1.3	263 $\pm$ 27
RV/TLC	71 $\pm$ 6%	176 $\pm$ 21	69 $\pm$ 4	173 $\pm$ 14
DL/VA	1.1 $\pm$ 0.5 ml/min/ mm Hg/L	29 $\pm$ 15	1.1 $\pm$ 0.5	28 $\pm$ 13
Pst at TLC	11 $\pm$ 1.7 cm H ₂ O	25 $\pm$ 7	11 $\pm$ 1.6	
Raw	5.1 $\pm$ 1.9 cm H ₂ O/lps	< 2.5	4.4 $\pm$ 1.4	
SGaw	0.032 $\pm$ 0.01 lps/cm H ₂ O/L	13 $\pm$ 6	0.03 $\pm$ 0.02	14 $\pm$ 7
Coefficient of retraction				
Pst at TLC/TLC	1.3 $\pm$ 0.4 cm H ₂ O/L	> 3.10	1.1 $\pm$ 0.1	
Gs	0.2 $\pm$ 0.10 lps/cm H ₂ O	0.6 $\pm$ 0.1	0.29 $\pm$ 0.09	
Vo ₂ max	5.7 $\pm$ 3.8 ml/kg/min	> 18	6.9 $\pm$ 1.4	
Dyspnea	3.2 $\pm$ 0.05	0	3.2 $\pm$ 0.04	
O ₂ Dependency	18	0	2	

Definition of abbreviations: DL/VA = diffusing capacity per liter of alveolar volume; dyspnea = dyspneic index; FEV₁ = forced expiratory volume in 1 s; FVC = forced vital capacity; Gs = conductance of S segment; LVRS = lung volume reduction surgery; Pst = static lung elastic recoil pressure; Raw = airway resistance; RV = residual volume; SGaw = specific airway conductance; TLC = total lung capacity; VC = vital capacity; Vo₂max = maximum oxygen consumption; O₂ dependency is part or full time.

* Values are mean $\pm$ SD. There was no statistical difference at baseline between 5 of 26 LVRS patients who had serial annual spirometry prior to LVRS, and the other 21 patients selected (data not shown) who only had preoperative baseline studies.

subgroup of five patients quit 3.3 $\pm$ 3.0 yr prior to LVRS, and two quit 6 mo prior to LVRS.

Actual survival at 0.5, 1, 2, 3, 4, and 5 yr post-LVRS was 96%, 96%, 81%, 69%, 54%, and 42%, respectively (see Figure 1). All deaths were related to respiratory failure, although concomitant lung malignancy was noted in two of four patients autopsied. Improvement in FEV₁ > 0.2 L, FVC > 0.4 L, or both was 88%, 73%, 46%, 35%, 27%, and 8% of all patients, respectively, and they are considered responders (see Figure 1). Six of nine patients at 3 yr, five of seven patients at 4 yr, and the two patients at 5 yr who demonstrated this physiological improvement post-LVRS had both FEV₁ > 0.2 L as well as FVC > 0.4 L when compared with baseline values.

There was a decrease in dyspnea grade $\geq$ 1 in 88%, 88%, 69%, 46%, 27%, and 15% of the 26 patients at 0.5, 1, 2, 3, 4, and 5 yr post-LVRS. Oxygen dependence (part or full time) present initially in 18 patients was eliminated in 78%, 78%,

50%, 33%, 22%, and 0% of surviving patients at 0.5, 1, 2, 3, 4, and 5 yr post-LVRS.

Maximum Expiratory Airflow

At 5 yr post-LVRS, we analyzed the mechanism(s) of improvement in expiratory airflow in the two long-term responder patients who increased both FEV₁ > 0.2 L and FVC > 0.4 L. Compared with preoperative baseline, the maximum expiratory flow volume curve demonstrated a reduction in both total lung capacity (TLC) and residual volume (RV), but more so in the latter, such that FVC increased (see Figure 2). Furthermore, maximum expiratory airflow at any lung volume was increased when compared with the same lung volume prior to LVRS, but still far below normal values. In these two patients, FEV₁ increased 210 ml and 460 ml, and FVC increased 710 ml and 470 ml, respectively, compared with baseline.

Figure 1. Results of survival, part- or full-time oxygen dependence, dyspnea, and lung function studies 0.5 to 5 yr post-LVRS. FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity.

Figure 2. In the two patients who increased $FEV_1 > 0.2$ L and $FVC > 0.4$ L from baseline to 5 yr post-LVRS, the maximum expiratory flow volume curve was shifted to the right, such that both TLC and RV decreased. The decrease in RV was greater, and FVC increased. Maximum expiratory airflow at any lung volume was greater compared with preoperative baseline, but still below age-matched normals. Actual results in one patient are shown; the other patient had similar results.

Lung Elastic Recoil

Prior to LVRS, these two patients had a marked reduction in static lung elastic recoil pressure at TLC: 9 and 12 cm H₂O (Figure 3). At 5 yr post-LVRS, elastic recoil pressures remained increased at TLC: 11 and 15 cm H₂O, respectively, and at all lung volumes compared with preoperative baseline, but still below normal values. Improvement in lung elastic recoil pressure held steady in the two patients between 1 and 4 yr after LVRS with deterioration at 5 yr post-LVRS.

Mechanism of Expiratory Airflow Limitation

Preoperatively, the slope (conductance small airway S segment, Gs) of the maximum expiratory airflow–static lung elastic recoil pressure (MFSR) curve was reduced compared with normal (6, 7) (Figure 4). This indicates that maximum expiratory airflow was reduced, not only because of loss of lung elastic recoil, but also due to suspected intrinsic small airways abnormalities and/or extrinsic collapse/obstruction of small airways. In the two long-term responders 5 yr after LVRS, maximum expiratory airflow increased, both due to greater lung elastic recoil as well as increased conductance of the S segment slope, reflecting better airway stability with less collapse/obstruction of flow-limiting segments. The increase in the S segment slope remained similar from 1 to 4 yr post-LVRS before deteriorating by 5 yr post-LVRS, but still greater than baseline.

Figure 3. In the two long-term (5 yr) patient responders, results of static lung elastic recoil pressure curve indicated increased lung elastic recoil at any given lung volume compared with baseline, but still below age-matched normals. Actual results in one patient are shown; the other patients had similar results.

Figure 4. In the two long-term (5 yr) patient responders, the improvement in maximum expiratory flow was due to both an increase in lung elastic recoil as well as increased slope (solid line) of flow–pressure relationships (Gs) of small airway. This indicates increased airway conductance (Gs) that could be accounted for, in part, by the increase in lung elastic recoil, and reflects increased airway caliber. The dashed line reflects the extension of Gs determined at effort-independent lung volumes to elastic recoil at TLC. Actual results are shown for one patient; the other patient had similar results.

Baseline Physiologic Tests

We previously reported (6) significant differences ($p < 0.01$) only for VC and FVC of all preoperative baseline parameters between long-term responders when compared with short-term responders. In the present study, sensitivity and specificity for baseline $FVC \geq 65\%$ predicted to detect patients who achieved $FEV_1 > 0.2$ L and/or $FVC > 0.4$ L at 3 yr post-LVRS is 56% and 71%, respectively, at 4 yr 71% and 74%, and at 5 yr post-LVRS 50% and 63%, respectively.

Follow-up of FEV_1 and FVC

In five patients with serial spirometry prior to LVRS, the decline in FEV_1 and FVC for 3.8 ± 0.4 yr prior to LVRS was 116 ± 110 ml/yr and 188 ± 154 ml/yr, respectively. After LVRS, following peak improvement and smoking cessation ≥ 6 mo, the subsequent deterioration in spirometry in each patient was similar ($p > 0.20$) to their pre-LVRS values. The FEV_1 decreased 141 ± 60 ml/yr and FVC 102 ± 189 ml/yr over 3.8 ± 1.2 yr post-LVRS with a fastest rate of decline within 1–2 yr after LVRS. In the 11 patients who survived 5 yr, at 0.5–1.0 yr post-LVRS the peak increase in FEV_1 was 438 ± 366 ml, with a decline of 149 ± 157 ml the following year and 78 ± 59 ml/yr over 4.0–4.5 yr (Figure 5).

Follow-up Exercise Study

Results of yearly exercise studies in three of 4–5 yr patient responders are reported in Table 2. Following LVRS, there was a modest increase in work performance with increase in oxygen saturation at rest and after exercise, such that all three patients became oxygen independent. Following LVRS, patients who initially improved, but subsequently returned to baseline spirometry and dyspnea values, showed no improvement in exercise performance compared with baseline (data not shown).

DISCUSSION

This prospective study, with no patients lost to follow-up, demonstrates that following bilateral LVRS for emphysema, using VATS technique, durable clinical and significant physiological improvement was achieved in 9 of 26 patients at 3 yr, 7 patients at 4 yr, and 2 patients at 5 yr. All patients had failed best medical therapy, including numerous rehabilitation efforts prior to LVRS.

Figure 5. The long-term changes in FEV₁ (A) and FVC (B) in five patients who had serial spirometry prior to LVRS and followed for 5 yr post-LVRS unless death intervened. The vertical line refers to LVRS intervention.

These observations, using very strict objective outcome criteria, were noted in elderly patients with end-stage emphysema with an anticipated high morbidity and mortality rate from respiratory failure based on historical cohort data (1–3).

Preoperatively, they had very severe airflow limitation, hyperinflation, markedly impaired exercise tolerance, and life-style with dyspnea limiting walking < 100 yd, and 18 of 26 patients required full- or part-time oxygen. Each patient served as their own control to evaluate the potential benefits of LVRS.

Clinical Outcome

The mortality rate due to respiratory failure of 4%, 4%, 19%, 31%, 46%, and 58% following LVRS in the present study at 0.5, 1, 2, 3, 4, and 5 yr is consistent with previous surgical studies reporting up to 3 yr follow-up.

Naunheim and coworkers (5) reported 1–3 yr mortality rate of 14%, 25%, and 31%, respectively, in 330 patients undergoing unilateral LVRS using VATS technique, and 10%, 19%, and 26% after bilateral LVRS in 343 patients. Patient selection, including baseline lung function and lung CT heterogeneity, was similar to the present study with 99% clinical follow-up. Lung function was reported only at 6 to 12 mo post-LVRS (8). However, patients' perceptions regarding improved quality of life and dyspnea relief at 2 yr after LVRS were between 71% and 88%, with bilateral LVRS yielding superior improvement (8).

Hamacher and workers (9) noted a mean increase of 36% from baseline FEV₁ in 16 patients studied with *marked heterogeneity* on lung CT 2 yr after bilateral LVRS using VATS technique, with 3% mortality. Alternatively, they noted only a 13% increase from baseline FEV₁ in 12 patients with lung CT *homogeneity* 2 yr after LVRS, with 23% mortality (6 of 26 patients). Relief from dyspnea was significantly improved ($p < 0.01$) in surviving patients at 2 yr following LVRS.

Flaherty and coworkers (10) noted improved clinical and exercise tolerance without corroborative increase in mean FEV₁ in seven patients followed for 3 yr after bilateral LVRS using a mediansternotomy technique, with a 3 yr mortality rate of 16% (14 of 89 patients). Although baseline lung function was similar to the present study, lung CT emphysema heterogeneity was not a surgical prerequisite.

Yusen and coworkers (11) noted a 1 to 5 yr actuarial mortality of 6%, 12%, 18%, 28%, and 38%, respectively, in 192 of 200 patients with lung CT heterogeneity who underwent bilateral LVRS using a mediansternotomy technique. Baseline lung function was similar to the present study. Approximately

TABLE 2. WORK PERFORMANCE BEFORE AND 5 yr AFTER LVRS IN THREE PATIENTS (A–C)

Time (yr)	$\dot{V}O_2\text{max}$ (ml/kg/min)	$\dot{V}_E$ (L/min)	Dyspnea Grade	O ₂ sat (%)		FEV ₁ (L) (% pred)	TLC (L) (% pred)	PST ₁ at TLC (cm H ₂ O)
				Rest	Peak Ex			
Baseline A	5.4	11	3	87	79	0.47 (30)	6.2 (162)	12
1 yr post	6.9	14	2	92	88	0.77 (51)	5.4 (141)	15
2 yr post	8.0	19	2	94	87	0.77 (51)	5.7 (149)	15
3 yr post	6.9	14	2	93	85	0.75 (50)	5.5 (146)	15
4 yr post	7.6	12	2	93	85	0.69 (38)	5.8 (153)	15
5 yr post	6.5	12	2	93	89	0.68 (37)	5.5 (147)	15
Baseline B	5.6	20	4	86	82	0.91 (37)	8.7 (148)	9
1 yr post	12.4	43	2	94	91	1.76 (71)	8.4 (143)	18
2 yr post	10.1	42	2	94	87	1.61 (65)	8.3 (141)	16
3 yr post	9.5	33	2	94	82	1.50 (59)	8.0 (136)	12
4 yr post	9.5	31	2	94	81	1.40 (55)	8.0 (136)	11
5 yr post	9.4	30	2	87	81	1.40 (55)	8.1 (137)	11
Baseline C	5.5	33	3	85	79	0.78 (27)	10.1 (172)	10
1 yr post	8.0	33	2	92	89	1.37 (49)	8.7 (149)	12
2 yr post	9.5	40	2	93	86	1.18 (43)	8.7 (149)	11
3 yr post	9.4	38	2	91	85	1.24 (45)	9.1 (156)	11
4 yr post	7.1	25	2	91	85	0.91 (32)	9.0 (156)	12
5 yr post	6.5	24	3	87	83	0.82 (30)	8.5 (146)	9

Definition of abbreviations: LVRS = lung volume reduction surgery; PST₁ at TLC = lung elastic recoil at total lung capacity; $\dot{V}_E$ = maximum minute ventilation at peak exercise; $\dot{V}O_2\text{max}$ = maximum oxygen consumption at peak exercise.

75% of surviving patients noted clinical improvement. Long-term lung function follow-up was not reported.

Pinto and coworkers (12) noted a 3-yr mortality rate of 30% in 18 patients following bilateral LVRS, with significant clinical improvement and mean increase in FEV₁ of 26% from baseline at 2 yr after LVRS.

In the present study, the mean age was 67 yr, similar to the studies of Hamacher and coworkers (9) and Naunheim and coworkers (5), whereas the mean age was 61 yr in the studies of Yusen and coworkers (11), 60 yr in Flaherty and coworkers (10), and 63 yr in Pinto and coworkers (12).

Surgical mortality risk for bilateral LVRS of 5% (11, 12), 5% (unilateral) (5), 7% (5), 6% (10), and 9% (9) were previously noted.

Comparing current patient results to historical (1–3) or similar nonrandomized case–controls (4) may be problematic because of clinical, pathological, and smoking history differences. However, using each patient as their own control does not systematically overestimate the magnitude of the effects of treatment as compared with those in randomized, controlled trials on the same topic (13).

An extensive review of LVRS experience has been reported (14). Three recently published randomized, controlled bilateral LVRS studies with crossover and 3–12 mo follow-up confirmed the short-term benefits of LVRS, including improvement in lung function, exercise tolerance, and quality of life (15–17). Unfortunately, for patient selection, other than upper lobe emphysema heterogeneity on lung CT baseline, lung function studies do not offer sufficient sensitivity and/or specificity to predict long-term improvement.

Decline in FEV₁ after LVRS

The present results are in agreement with our previously reported (18) decline in FEV₁ of 255 ± 57 ml/yr in 90 patients post-LVRS with mean follow-up of only 420 ± 15 d. The fastest decline in FEV₁ was noted 1–2 yr following LVRS. Furthermore, we previously noted a weak correlation between short-term increase in FEV₁ post-LVRS and long-term rate in decline in FEV₁ (r = 0.162, p = 0.29) (18). There are obvious limitations to data interpretation including comparison of post-LVRS nonsmokers with pre-LVRS smokers, and comparison of FEV₁ decline from varying lung volumes with different mechanical properties.

Dyspnea and Exercise Tolerance Post-LVRS

The improvement in dyspnea and exercise tolerance following LVRS best correlates with the reduction in hyperinflation and increase in transdiaphragmatic pressure due to repositioning of the diaphragm with recruitment of inspiratory respiratory muscles (19–23) and increased neuromechanical coupling (23), often irrespective of changes in FEV₁. Our limited 5-yr exercise results in three patients confirm the imperfect relationship among dyspnea, lung function, work performance, and oxygen saturation (see Table 2). We believe the persistent reduction in hyperinflation and subsequent increase in transdiaphragmatic pressure are consequent to the maintained increase in lung elastic recoil following LVRS.

In summary, LVRS provided significant clinical and physiological improvement in 9 of 26 selected patients up to 3 yr, 7 at 4 yr, and 2 at 5 yr.

Acknowledgment: The authors thank Randy Newsom, CPFT/RCP, for pulmonary function testing, Christy Kirkendall for patient coordination, and Chris Shinar, Pharm. D., for illustrations.

References

1. Anthonisen NR. Prognosis in chronic obstructive pulmonary disease: re-

- sults from multicenter clinical trials. *Am Rev Respir Dis* 1989;140:595–599.
2. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease: a prospective study of 200 patients. *N Engl J Med* 1969;280:397–404.
3. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WE. Hospital and 1 year survival of patients admitted in intensive care units with exacerbation of chronic obstructive pulmonary disease. *JAMA* 1995;274:1852–1857.
4. Meyers BF, Yusem RD, Lefrak SS, Patterson GA, Pohl MA, Richardson VJ, Cooper JD. Outcome of Medicare patients with emphysema selected for, but denied, a lung volume reduction operation. *Ann Thorac Surg* 1998;66:331–336.
5. Naunheim KS, Kaiser LR, Bavaria JE, Hazelrigg SR, Magee M, Landreneau RJ, Keenan RJ, Osterloh JF, Boley TM, Keller CS. Long-term survival after thoracoscopic lung volume reduction: a multistitutional review. *Ann Thorac Surg* 1999;68:2026–2032.
6. Gelb AF, McKenna RJ Jr, Brenner M, Schein MJ, Fischel R, Zamel N. Lung function 4 years after lung volume reduction surgery for emphysema. *Chest* 1999;116:1608–1615.
7. Gelb AF, Zamel N, McKenna RJ Jr, Brenner M. Mechanism of short-term improvement in lung function following emphysema resection. *Am J Respir Crit Care Med* 1996;154:945–951.
8. Lowdermilk GA, Keenan RJ, Landreneau RJ, Hazelrigg SR, Bavaria JE, Kaiser LR, Keller CA, Naunheim KS. Comparison of clinical results for unilateral and bilateral thoracoscopic lung volume reduction. *Ann Thorac Surg* 2000;69:1670–1674.
9. Hamacher J, Bloch K, Stammberger U, Schmid RA, Laube I, Russi EW, Weder W. Two years' outcome of lung volume reduction surgery in different morphologic emphysema types. *Ann Thorac Surg* 1999;68:1792–1798.
10. Flaherty K, Christensen P, Paine R, Iannettoni M, Meldrum K, Meldrum M, Kazerooni E, Ojo-Clark T, Martinez F. Thirty-six month follow-up of patients following lung volume reduction surgery (LVRS) [abstract]. *Am J Respir Crit Care Med* 1999;159:A923.
11. Yusem RD, Pohl MS, Biggar DC, Davis GE, Lefrak SS, Cooper JD. Outcomes through 5 yr after lung volume reduction surgery. *Chest* 1999;116:376S.
12. Pinto V, Livnat G, Stetz J, Rassulo J, Celli B. Physiologic outcome of patients with severe COPD who underwent lung volume reduction surgery (LVRS) vs non operated candidates. [abstract] *Am J Respir Crit Care Med* 2000;161:A585.
13. Corcato J, Shah N, Horowitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med* 2000;342:1887–1892.
14. Flaherty KR, Martinez FJ. Lung volume reduction surgery for emphysema. *Clin Chest Med* 2000;21:819–848.
15. Criner GJ, Cordova FC, Furukawa S, Kuzma AM, Travaline JM, Leyenson V, O'Brien GM. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;160:2018–2027.
16. Geddes D, Davies M, Koyoma H, Hansell D, Pastorino U, Pepper J, Agent P, Cullinan P, MacNeill SJ, Goldstraw P. Effect of lung volume reduction surgery in patients with emphysema. *N Engl J Med* 2000;343:239–245.
17. Pompeo E, Marino M, Nofroni I, Matteuci G, Mineo TC. Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. *Ann Thorac Surg* 2000;70:948–953.
18. Brenner M, McKenna RJ Jr, Gelb AF, Fischel RJ, Wilson AF. Rate of FEV₁ change following lung volume reduction surgery. *Chest* 1998;113:652–659.
19. Martinez FJ, Montes de Oca M, Whyte RI, Stetz J, Gay SE, Celli BR. Lung volume reduction surgery improves dyspnea, dynamic hyperinflation and respiratory muscle function. *Am J Respir Crit Care Med* 1997;155:1984–1990.
20. O'Donnell DE, Webb KA, Bertley JC, Chau L, Conlan A. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. *Chest* 1996;110:18–27.
21. Benditt JO, Wood DE, McCool FD, Lewis S, Albert R. Changes in breathing and ventilatory muscle recruitment patterns induced by lung volume reduction surgery. *Am J Respir Crit Care Med* 1997;155:279–284.
22. Criner G, Cordova FC, Leyenson V, Roy B, Travaline J, Sudarshan S, O'Brien G, Kuzma AM, Furukawa S. Effect of lung volume reduction surgery on diaphragm strength. *Am J Respir Crit Care Med* 1998;157:1578–1585.
23. Laghi F, Jubran A, Topeli A, Fahey PJ, Garrity ER Jr, Arcidi JM, de Pinto DJ, Edwards LC, Tobin MJ. Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm. *Am J Respir Crit Care Med* 1998;157:475–483.